XORTX THERAPEUTICS INC (XRTX) Stock Price, Quote, News and Overview
NASDAQ:XRTX - Nasdaq - CA98420Q3061 - Common Stock - Currency: USD
XRTX Quote, Performance and Key Statistics
1.02
-0.01 (-0.97%)
The current stock price of XRTX is 1.02 USD. In the past month the price increased by 22.73%. In the past year, price decreased by -59.52%.
XRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 53.38 | 696.37B | ||
| JNJ | JOHNSON & JOHNSON | 15.35 | 371.06B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.85 | 291.96B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.08 | 214.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.16 | 209.49B | ||
| MRK | MERCK & CO. INC. | 9.75 | 191.17B | ||
| PFE | PFIZER INC | 6.94 | 126.36B | ||
| SNY | SANOFI-ADR | 13.03 | 122.16B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.33 | 94.53B | ||
| GSK | GSK PLC-SPON ADR | 6.69 | 74.10B | ||
| ZTS | ZOETIS INC | 26.46 | 71.04B | ||
| HLN | HALEON PLC-ADR | 21.92 | 48.43B |
Related stock screener links
About XRTX
Company Profile
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. The company is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The firm has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The firm's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
Company Info
XORTX THERAPEUTICS INC
3710 - 33rd Street NW
Calgary ALBERTA CA
Employees: 3
Phone: 14034557727
XORTX THERAPEUTICS INC / XRTX FAQ
What is the stock price of XORTX THERAPEUTICS INC today?
The current stock price of XRTX is 1.02 USD. The price decreased by -0.97% in the last trading session.
What is the ticker symbol for XORTX THERAPEUTICS INC stock?
The exchange symbol of XORTX THERAPEUTICS INC is XRTX and it is listed on the Nasdaq exchange.
On which exchange is XRTX stock listed?
XRTX stock is listed on the Nasdaq exchange.
What is XORTX THERAPEUTICS INC worth?
XORTX THERAPEUTICS INC (XRTX) has a market capitalization of 3.87M USD. This makes XRTX a Nano Cap stock.
How many employees does XORTX THERAPEUTICS INC have?
XORTX THERAPEUTICS INC (XRTX) currently has 3 employees.
What are the support and resistance levels for XORTX THERAPEUTICS INC (XRTX) stock?
XORTX THERAPEUTICS INC (XRTX) has a support level at 1.01 and a resistance level at 1.06. Check the full technical report for a detailed analysis of XRTX support and resistance levels.
Should I buy XORTX THERAPEUTICS INC (XRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XRTX, evaluating the profitability, health, valuation and growth aspects
- XORTX THERAPEUTICS INC (XRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- XORTX THERAPEUTICS INC (XRTX) Sales and EPS estimates to see what analysts future expectations are.
- XORTX THERAPEUTICS INC (XRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- XORTX THERAPEUTICS INC (XRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- XORTX THERAPEUTICS INC (XRTX) Stock Chart to make your own analysis
- XORTX THERAPEUTICS INC (XRTX) Latest news and press-releases to stay up to date.
Does XORTX THERAPEUTICS INC (XRTX) stock pay dividends?
XRTX does not pay a dividend.
When does XORTX THERAPEUTICS INC (XRTX) report earnings?
XORTX THERAPEUTICS INC (XRTX) will report earnings on 2025-05-14.
What is the Price/Earnings (PE) ratio of XORTX THERAPEUTICS INC (XRTX)?
XORTX THERAPEUTICS INC (XRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.35).
What is the Short Interest ratio of XORTX THERAPEUTICS INC (XRTX) stock?
The outstanding short interest for XORTX THERAPEUTICS INC (XRTX) is 0.86% of its float. Check the ownership tab for more information on the XRTX short interest.
XRTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to XRTX. When comparing the yearly performance of all stocks, XRTX is a bad performer in the overall market: 80.78% of all stocks are doing better.
XRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XRTX. The financial health of XRTX is average, but there are quite some concerns on its profitability.
XRTX Financial Highlights
Over the last trailing twelve months XRTX reported a non-GAAP Earnings per Share(EPS) of -1.35. The EPS decreased by -21.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.92% | ||
| ROE | -99.3% | ||
| Debt/Equity | 0 |
XRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to XRTX. The Buy consensus is the average rating of analysts ratings from 5 analysts.